New York-Some prostate cancer patients may be running to the healthfood store for supplements like PC-SPES, but the supplement cannot competewith other tried and true hormonal therapies, at least in men with androgen-dependentdisease, according to William Oh, MD.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.